Lakewood Capital Management LP Purchases Shares of 317,900 IQVIA Holdings Inc. $IQV

Lakewood Capital Management LP purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the 2nd quarter, HoldingsChannel reports. The fund purchased 317,900 shares of the medical research company’s stock, valued at approximately $61,425,000. IQVIA makes up 3.2% of Lakewood Capital Management LP’s holdings, making the stock its 11th largest position.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in IQVIA in the second quarter valued at approximately $2,811,292,000. Boston Partners bought a new position in IQVIA during the 3rd quarter worth approximately $676,698,000. Norges Bank acquired a new position in shares of IQVIA in the 4th quarter worth approximately $497,445,000. Victory Capital Management Inc. boosted its stake in shares of IQVIA by 2,628.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,675,479 shares of the medical research company’s stock valued at $377,670,000 after purchasing an additional 1,614,063 shares during the last quarter. Finally, Legal & General Group Plc acquired a new stake in shares of IQVIA during the second quarter worth $211,342,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IQV has been the subject of a number of analyst reports. JPMorgan Chase & Co. boosted their target price on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Royal Bank Of Canada increased their price target on IQVIA from $221.00 to $247.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Morgan Stanley reissued an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research report on Thursday, July 9th. Finally, TD Cowen raised their target price on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $241.88.

Insider Transactions at IQVIA

In other IQVIA news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the sale, the insider owned 1,348 shares of the company’s stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 558 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 in the last three months. Insiders own 1.70% of the company’s stock.

IQVIA Trading Up 0.2%

IQV opened at $260.30 on Tuesday. The company has a fifty day moving average price of $214.97 and a two-hundred day moving average price of $187.62. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $261.88. The company has a market cap of $42.85 billion, a P/E ratio of 32.30, a price-to-earnings-growth ratio of 2.21 and a beta of 1.18. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter in the prior year, the firm earned $2.81 EPS. The business’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts predict that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA declared that its board has authorized a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.